Poised for Growth

With a pipeline of promising therapeutics, Merakris is well positioned to be at the forefront of the cellular regenerative market which is expected to reach $40 billion by 2027, driven by rising healthcare costs and increasing demand for innovative treatment options.

Our investors and partners make it possible to pioneer new regenerative treatment options and provide access to our patients and providers across the globe.